GlassScriptPhysician profile
Dheeraj Reddy
NPI 1871804757
$7,939.82
in general payments reported to CMS, 2019-2025
44 companies · $3,202 in 2025
The $3,202 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $15.34 · 2023: $1,643 · 2024: $3,067 · 2025: $3,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,228 · Consulting Fee: $1,500 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,227.58 |
| Consulting Fee | $1,500.00 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,166.32 | 2023-2025 | Imfinzi, Enhertu, Calquence |
| Glaxosmithkline, LLC. | $1,060.24 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Tempus Ai, INC | $481.60 | 2024-2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $445.65 | 2022-2025 | Opdivo, Eliquis |
| Sobi, INC | $391.54 | 2023-2025 | |
| Daiichi Sankyo INC. | $387.10 | 2023-2025 | Enhertu |
| Gilead Sciences, INC. | $378.05 | 2021-2025 | Trodelvy |
| Pfizer INC. | $325.79 | 2023-2025 | |
| Pharmaessentia USA Corporation | $292.91 | 2023-2025 | Besremi |
| Astellas Pharma US INC | $259.64 | 2024-2025 | Padcev, Vyloy, Xtandi |
| Merck Sharp & Dohme LLC | $248.39 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Novartis Pharmaceuticals Corporation | $242.44 | 2023-2025 | |
| Abbvie INC. | $209.96 | 2024-2025 | |
| Genentech USA, INC. | $183.92 | 2023-2025 | Tecentriq, Polivy, Tecentriq Hybreza |
| Bayer Healthcare Pharmaceuticals INC. | $164.52 | 2023-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $159.72 | 2023-2025 | Monjuvi, Jakafi |
| Array Biopharma INC | $156.90 | 2024-2025 | Braftovi, Mektovi, Xalkori |
| Janssen Biotech, INC. | $141.71 | 2024-2025 | Rybrevant, Akeega, Erleada |
| Shield Therapeutics INC | $125.63 | 2024 | |
| Jazz Pharmaceuticals INC. | $121.26 | 2023-2025 | Zepzelca |
| Celgene Corporation | $90.39 | 2025 | Reblozyl |
| Dendreon Pharmaceuticals LLC | $81.18 | 2023-2025 | Provenge |
| Geron Corporation | $73.83 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $68.57 | 2024-2025 | Xpovio |
| Sirtex Medical INC | $68.09 | 2023-2024 | Sir-Spheres Microspheres |
| Aveo Pharmaceuticals, INC. | $55.44 | 2024 | |
| Stemline Therapeutics INC. | $55.30 | 2024-2025 | Orserdu |
| Genzyme Corporation | $52.48 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $45.72 | 2024-2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $44.74 | 2023 | Tavalisse, Rezlidhia |
| Cti Biopharma Corp. | $38.88 | 2023 | Vonjo |
| Morphosys, US INC. | $38.61 | 2023 | Monjuvi |
| Caris Mpi, INC. | $34.09 | 2025 | Mi Cancer Seek |
| Eisai INC. | $33.33 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.54 | 2024 | Iclusig |
| Beigene USA, INC. | $29.45 | 2024 | Brukinsa |
| Lilly USA, LLC | $23.78 | 2024 | Verzenio, Jaypirca |
| Mirati Therapeutics, INC. | $23.45 | 2023 | Krazati |
| Kyowa Kirin, INC. | $22.98 | 2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.87 | 2025 | |
| Nestle Healthcare Nutrition INC. | $19.69 | 2023 | |
| Genmab U.S., INC. | $16.20 | 2023 | Epkinly |
| Amgen INC. | $13.69 | 2023 | Lumakras |
| Seagen INC. | $13.23 | 2023 | Padcev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dheeraj Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.